2021
Ubiquitination of ATF6 by disease-associated RNF186 promotes the innate receptor-induced unfolded protein response
Ranjan K, Hedl M, Sinha S, Zhang X, Abraham C. Ubiquitination of ATF6 by disease-associated RNF186 promotes the innate receptor-induced unfolded protein response. Journal Of Clinical Investigation 2021, 131: e145472. PMID: 34623328, PMCID: PMC8409591, DOI: 10.1172/jci145472.Peer-Reviewed Original ResearchMeSH KeywordsActivating Transcription Factor 6AnimalsEndoplasmic Reticulum StressGenetic VariationHost Microbial InteractionsHumansImmunity, InnateInflammatory Bowel DiseasesMacrophagesMiceMice, Inbred C57BLMice, KnockoutNod2 Signaling Adaptor ProteinReceptors, Pattern RecognitionRisk FactorsSignal TransductionUbiquitinationUbiquitin-Protein LigasesUnfolded Protein ResponseConceptsPattern recognition receptorsUnfolded protein responseInflammatory bowel diseaseER stress sensorsHuman macrophagesIntestinal immune homeostasisProtein responseInnate immune systemRisk variantsKey macrophage functionsBowel diseaseOral challengeTranscription factor 6Immune homeostasisCytokine secretionColonic tissueMacrophage functionStress sensorImmune systemRecognition receptorsEffective clearanceMicrobial responsesWeight lossMacrophagesUbiquitinationCheckpoint Inhibitor Colitis Shows Drug-Specific Differences in Immune Cell Reaction That Overlap With Inflammatory Bowel Disease and Predict Response to Colitis Therapy
Lo YC, Price C, Blenman K, Patil P, Zhang X, Robert ME. Checkpoint Inhibitor Colitis Shows Drug-Specific Differences in Immune Cell Reaction That Overlap With Inflammatory Bowel Disease and Predict Response to Colitis Therapy. American Journal Of Clinical Pathology 2021, 156: 214-228. PMID: 33555016, DOI: 10.1093/ajcp/aqaa217.Peer-Reviewed Original ResearchConceptsInflammatory bowel diseaseCD8/FOXP3 ratioBiopsy specimensCPI patientsPD-1CD68 scoreFOXP3 ratioBowel diseasePD-L1Antibody-treated patientsCheckpoint inhibitor colitisPD-L1 groupInitial biopsy specimensPD-L1 expressionImmune cell reactionsColonic biopsy specimensDrug-specific differencesIBD groupCheckpoint inhibitorsChronicity scoreActivity scoreImmune phenotypeTherapeutic responseColitisShared pathophysiology
2020
Gastrointestinal Ischemia and Vascular Disorders
Celli R, Zhang X. Gastrointestinal Ischemia and Vascular Disorders. 2020, 84-101. DOI: 10.1017/9781316823026.007.Peer-Reviewed Original ResearchMorphological spectrum of immune check‐point inhibitor therapy‐associated gastritis
Johncilla M, Grover S, Zhang X, Jain D, Srivastava A. Morphological spectrum of immune check‐point inhibitor therapy‐associated gastritis. Histopathology 2020, 76: 531-539. PMID: 31692018, DOI: 10.1111/his.14029.Peer-Reviewed Original ResearchConceptsImmune check-point inhibitor therapyCheck-point inhibitor therapyImmune-related adverse eventsImmune check point inhibitorsMorphological spectrumIntra-epithelial lymphocytosisCheck point inhibitorsChronic active gastritisInflammatory bowel diseaseMedical chart reviewCytotoxic T cellsDrug-induced gastritisPredominant histological patternDistribution of injuriesVariety of tumorsMechanism of actionSteroid therapyGastrointestinal injuryActive gastritisAdverse eventsChart reviewClinical suspicionMedication withdrawalBowel diseaseInhibitor therapy